A1 Refereed original research article in a scientific journal
Pharmacotherapy and generic health-related quality of life in Parkinson's disease
Authors: Järvelä J, Kaasinen V
Publisher: WILEY-BLACKWELL
Publication year: 2016
Journal: Acta Neurologica Scandinavica
Journal name in source: ACTA NEUROLOGICA SCANDINAVICA
Journal acronym: ACTA NEUROL SCAND
Volume: 134
Issue: 3
First page : 205
Last page: 209
Number of pages: 5
ISSN: 0001-6314
DOI: https://doi.org/10.1111/ane.12531
Abstract
ObjectivesImprovement of health-related quality of life (HRQoL) is one of the primary objectives of symptomatic therapies in Parkinson's disease (PD). The aim of this observational study was to investigate possible changes in generic HRQoL in relation to changed PD pharmacotherapy in the clinical setting.Materials & methodsA total of 219 outpatients with mild to moderate PD (median H&Y score=2.0), treated with oral antiparkinsonian medications, were investigated twice with a 6-month interval. At baseline, PD medication dose was increased for 82 patients for clinical reasons (median increase of 100mg levodopa equivalent daily dose or 31.9%), whereas medication remained unchanged for 137 patients. Two generic HRQoL questionnaires, EQ-5D and 15D, were used at baseline and at 6months, and the baseline and delta HRQoL values were compared between the treatment groups.ResultsIn the entire sample, the EQ-VAS score decreased during the study period, indicating a general decline in HRQoL (P=0.04). There were no differences in the baseline HRQoL values or delta values between the treatment groups as measured with EQ-5D or 15D (levodopa dose elevated vs dopamine agonist/MAO-B inhibitor dose elevated vs no change in medication).ConclusionsAn approximately 1/3 increase in antiparkinsonian medication dose did not have an impact on generic HRQoL. Disease-specific QoL may be more sensitive to pharmacotherapy-related changes in PD.
ObjectivesImprovement of health-related quality of life (HRQoL) is one of the primary objectives of symptomatic therapies in Parkinson's disease (PD). The aim of this observational study was to investigate possible changes in generic HRQoL in relation to changed PD pharmacotherapy in the clinical setting.Materials & methodsA total of 219 outpatients with mild to moderate PD (median H&Y score=2.0), treated with oral antiparkinsonian medications, were investigated twice with a 6-month interval. At baseline, PD medication dose was increased for 82 patients for clinical reasons (median increase of 100mg levodopa equivalent daily dose or 31.9%), whereas medication remained unchanged for 137 patients. Two generic HRQoL questionnaires, EQ-5D and 15D, were used at baseline and at 6months, and the baseline and delta HRQoL values were compared between the treatment groups.ResultsIn the entire sample, the EQ-VAS score decreased during the study period, indicating a general decline in HRQoL (P=0.04). There were no differences in the baseline HRQoL values or delta values between the treatment groups as measured with EQ-5D or 15D (levodopa dose elevated vs dopamine agonist/MAO-B inhibitor dose elevated vs no change in medication).ConclusionsAn approximately 1/3 increase in antiparkinsonian medication dose did not have an impact on generic HRQoL. Disease-specific QoL may be more sensitive to pharmacotherapy-related changes in PD.
UTU Research Portal